semaglutide discontinuation Weight maintenance after of GLP-1 therapies Majority of adults with obesity

Practice guidelines for preoperative fasting and the use of pharmacologic agents to reduce the risk of pulmonary aspiration

For current practice, the most defensible use of GLP-1RAs is as a time-bounded metabolic optimization strategy in women with meaningful obesity/insulin-resistance burden, with reproductive endpoints interpreted as potential downstream gains rather than guaranteed direct effects (111, 112, 124)

Rajeswari, A., Christy, E

In a 48-week study enrolling 263 overweight adults, patients receiving the lowest dose of eloralintide lost 9.5% of their body weight, while those on the highest dose lost 20%

Ann Oncol 2021;32:208217 [DOI] [PubMed] [Google Scholar] 253

Tell us the sources, topics and places you care about and we'll create a news channel made just for you called "My Headlines" from more than 400 different trusted channels